Literature DB >> 28616611

Technical success and short-term results of surgical treatment of gastrointestinal stromal tumors: an experience of three centers.

Mark Igorevich Gluzman1,2, Victor Anatolevich Kashchenko1,2, Aleksei Mikhailovich Karachun3, Rashida Vakhidovna Orlova2, Iakov Aleksandrovich Nakatis1,2, Iurii Vasilevich Pelipas3, Evgenia Leonidovna Vasiukova1,2, Ivan Vladimirovich Rykov1,2, Veronika Vladimirovna Petrova2,4, Svetlana Leonidovna Nepomniashchaia4, Anton Sergeevich Klimov1,2.   

Abstract

BACKGROUND: Gastrointestinal stromal tumors (GIST) comprise about 80% of gastrointestinal sarcomas. In patients with localized disease, surgery is considered as "Gold Standard" treatment. Organ-sparing radical en-block resection is widely accepted practice. Since lymph node dissection is not routinely indicated, minimally invasive approach is of particular interest. The aim of this study is to investigate the short-term outcomes of different surgical treatment of GISTs.
METHODS: We analyzed data of 116 patients who received surgical treatment for localized forms of GIST. Tumors were located in the stomach in 87 (75%) cases, in the small intestine in 26 (22.4%) cases, and extragastrointestinal GISTs were found in 3 (2.6%) patients. Four different approaches were used-open surgery (OpS, n=48), laparoscopic surgery (LS, n=40), endoscopic procedures (EP, n=22) and hybrid rendezvous (HR, n=6). Patient demographics, clinical presentation of tumors, characteristics of operation procedures (duration, intraoperative blood loss, frequency of R0-resection and fragmentation of tumor), postoperative complications and length of hospital stay were examined in all these groups.
RESULTS: Radical treatment (R0-resection) was performed in all patients. There were no cases of tumor ruptures during surgical procedure. Mean size of GIST in OpS was 9.1±2.0 [2-35] cm; in LS: 4.9±0.8 (1.5-15) cm; in HR: 3.5±0.8 (2-4.5) cm and in EP: 2.3±0.3 (0.4-3.5) cm. Intraoperative blood loss in OpS was 369.7±209.5 [0-4,000] mL; LS: 63.9±16.0 [0-150] mL; in HR: 96.7±44.3 [50-200] mL; in EP: 33.3±11.0 [0-150] mL. Duration of operation in OpS was 160±20.4 [50-310] min; in LS: 104.7±12.7 [50-185]; in HR: 176.7±44.0 [110-260] min and in EP: 89.8±15.5 [25-190] min. Complication rate in OpS was 5 (10.4%); in LS: 3 (7.5%); in HR: 0% and in EP: 3 (13.6%). Length of hospital stay in OpS was 13.8±2.2 [7-52] days; in LS: 11, 4±2.2 [4-21] days; in HR: 11±3.2 [7-15] days and in EP: 11, 9±2.1 [5-22] days. There were no postoperative deaths.
CONCLUSIONS: There is a diversity of surgical approaches for GISTs treatment. From our point of view, the main selection criteria for certain procedure are size, localization, growth type of the tumor and status of overlying mucosa. Nevertheless, due to relative rarity and heterogeneity of this pathology, individualization is necessary in each specific case. Laparoscopic and endoscopic surgery is proved to be safe and feasible for resection of the gastric GISTs, with a reasonable operation time, low blood loss, and an acceptable complication rate. Immediate results indicate that all interventions were performed radically without mortality or serious morbidity.

Entities:  

Keywords:  Gastrointestinal stromal tumors (GIST); endoscopic full thickness resections (EFTR); endoscopic submucosal dissection (ESD); laparoscopic wedge resections; submucosal tunnel endoscopic resections (STER)

Year:  2017        PMID: 28616611      PMCID: PMC5460099          DOI: 10.21037/tgh.2017.05.04

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  22 in total

1.  Endoscopic submucosal dissection for the treatment of intraluminal gastric subepithelial tumors originating from the muscularis propria layer.

Authors:  I-L Lee; P Y Lin; S-Y Tung; C-H Shen; K-L Wei; C-S Wu
Journal:  Endoscopy       Date:  2006-10       Impact factor: 10.093

2.  Successful gastric submucosal tumor resection using laparoscopic and endoscopic cooperative surgery.

Authors:  Hironori Tsujimoto; Yoshihisa Yaguchi; Isao Kumano; Risa Takahata; Satoshi Ono; Kazuo Hase
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

Review 3.  Laparoscopic versus open resection of gastrointestinal stromal tumors of the stomach.

Authors:  Kristel De Vogelaere; Anne Hoorens; Patrick Haentjens; Georges Delvaux
Journal:  Surg Endosc       Date:  2012-12-12       Impact factor: 4.584

4.  Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Authors:  Ramzi Dagher; Martin Cohen; Gene Williams; Mark Rothmann; Jogarao Gobburu; Gabriel Robbie; Atiqur Rahman; Gang Chen; Ann Staten; Donna Griebel; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

5.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

6.  Preliminary experience of endoscopic submucosal tunnel dissection for upper gastrointestinal submucosal tumors.

Authors:  W Gong; Y Xiong; F Zhi; S Liu; A Wang; B Jiang
Journal:  Endoscopy       Date:  2012-02-21       Impact factor: 10.093

Review 7.  Current management of gastrointestinal stromal tumors: Surgery, current biomarkers, mutations, and therapy.

Authors:  Nakul Valsangkar; Amikar Sehdev; Subhasis Misra; Teresa A Zimmers; Bert H O'Neil; Leonidas G Koniaris
Journal:  Surgery       Date:  2015-08-01       Impact factor: 3.982

Review 8.  Gastrointestinal stromal tumors.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  Gastroenterol Clin North Am       Date:  2013-03-13       Impact factor: 3.806

9.  Over-the-scope clip-assisted method for resection of full-thickness submucosal lesions of the gastrointestinal tract.

Authors:  Shabnam Sarker; Juan Pablo Gutierrez; Leona Council; Jason D Brazelton; Kondal R Kyanam Kabir Baig; Klaus Mönkemüller
Journal:  Endoscopy       Date:  2014-05-15       Impact factor: 10.093

Review 10.  Current Techniques for Treating Gastrointestinal Stromal Tumors in the Upper Gastrointestinal Tract.

Authors:  Weon Jin Ko; Joo Young Cho
Journal:  Clin Endosc       Date:  2016-05-23
View more
  5 in total

Review 1.  Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries.

Authors:  Fadi Farhat; Abdulaziz Al Farsi; Ahmed Mohieldin; Bassim Al Bahrani; Eman Sbaity; Hassan Jaffar; Joseph Kattan; Kakil Rasul; Khairallah Saad; Tarek Assi; Waleed El Morsi; Rafid A Abood
Journal:  World J Clin Cases       Date:  2020-02-06       Impact factor: 1.337

2.  Comparison Among Endoscopic, Laparoscopic, and Open Resection for Relatively Small Gastric Gastrointestinal Stromal Tumors (<5 cm): A Bayesian Network Meta-Analysis.

Authors:  Zhen Liu; Ziyang Zeng; Siwen Ouyang; Zimu Zhang; Juan Sun; Xianze Wang; Xin Ye; Weiming Kang; Jianchun Yu
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

3.  Comparison of Prognosis Between Microscopically Positive and Negative Surgical Margins for Primary Gastrointestinal Stromal Tumors: A Systematic Review and Meta-Analysis.

Authors:  Zhen Liu; Yichunzi Zhang; Han Yin; Xiuzhu Geng; Sishang Li; Jinrong Zhao; Ziyang Zeng; Xin Ye; Jianchun Yu; Fan Feng; Weiming Kang
Journal:  Front Oncol       Date:  2022-04-19       Impact factor: 5.738

4.  Comparative Study on the Clinical Effects of Different Surgical Methods in the Treatment of Gastrointestinal Stromal Tumors.

Authors:  Jinyan Wu; Boneng Mao; Tao Jin; Xinfang Xu; Xiao Xu; Shengjun Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-21       Impact factor: 2.650

5.  Endoscopic full-thickness resection for treating small tumors originating from the muscularis propria in the gastric fundus: An improvement in technique over 15 years.

Authors:  Nan Ge; Jin-Long Hu; Fei Yang; Fan Yang; Si-Yu Sun
Journal:  World J Gastrointest Oncol       Date:  2019-11-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.